Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Renal and Hepatic Considerations in Older PWH

In this on-demand recording of a live webinar, expert faculty review key renal and hepatic considerations, such as how to choose ART and what to monitor in older PWH.
Jonathan Appelbaum, MD, FACP, AAHIVS
Jens D. Lundgren, MD, DMSc
Released: February 10, 2022

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for antiretroviral therapy (ART) use in older patients with renal and hepatic impairment.

  • European AIDS Clinical Society guideline screening recommendations for kidney disease in people with HIV
  • Antiretroviral dose adjustment recommendations based on estimated glomerular filtration rate
  • Data on the use of full-dose lamivudine with renal impairment
  • Data on the use of 2-drug nucleos(t)ide reverse-transcriptase inhibitor–sparing ART regimens, including GEMINI-1 and -2, TANGO, and SALSA for dolutegravir/lamivudine; SWORD-1 and -2 for dolutegravir/lamivudine; and ATLAS and FLAIR for long-acting cabotegravir plus rilpivirine
  • US Department of Health and Human Services recommendations on the use of ART agents with hepatic impairment
  • Recommendations from the American Gastroenterological Association on screening and diagnosis of nonalcoholic fatty liver disease (NAFLD)
  • Prevalence of NAFLD, nonalcoholic steatohepatitis, and liver fibrosis in people with HIV
  • Overlapping risk factors between HIV and NAFLD

Information on this Educational Activity

Faculty

Jonathan Appelbaum, MD, FACP, AAHIVS

Laurie L. Dozier Jr, MD, Education Director
Professor of Internal Medicine
Chair,
Department of Clinical Sciences
Florida State University College of Medicine
Tallahassee, Florida

Jonathan Appelbaum, MD, FACP, AAHIVS, has disclosed that he has received consulting fees from Merck and ViiV.
Jens D. Lundgren, MD, DMSc

Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark

Jens D. Lundgren, MD, DMSc, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

Listen to expert faculty discuss strategies to promote ART safety and tolerability in aging patients and populations with cardiometabolic toxicities, from Clinical Care Options (CCO)

Marta Boffito, MD, PhD, FRCP Jens D. Lundgren, MD, DMSc Released: January 17, 2023

Slides on HIV ART management in complex clinical situations, including extensive previous treatment, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: January 11, 2023

Slides on HIV ART management in complex clinical situations, including extensive previous treatment, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: January 10, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings